Vinblastine

General description

INN	Vinblastine
ATC codes	L01CA01
Medicine type	Chemical agent
EML status history	First added in 1984 (TRS 722) for Unspecified malignant neoplasms of unspecified sites Changed in 2015 (TRS 994) for Hodgkin lymphoma Changed in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site Changed in 2015 (TRS 994) for Germ cell tumour of testis Changed in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of unspecified sites Added in 2021 (TRS 1035) for Other specified gliomas of brain Changed in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Changed in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative Changed in 2023 (TRS 1049) for Langerhans cell histiocytosis
Wikipedia	Vinblastine
DrugBank	Vinblastine

Recommendations

Section Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of unspecified sites

Other specified gliomas of brain

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis